AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Picard Medical shares surge 27.71% premarket after showcasing Emperor TAH in vitro data and successful in vivo implantation.
ByAinvest
Friday, Dec 5, 2025 4:01 am ET1min read
Picard Medical surged 27.71% in premarket trading following the presentation of in vitro and in vivo data on its Emperor Total Artificial Heart (TAH) at an international conference. The Emperor TAH demonstrated autoregulation and afterload independence in vitro, eliminated the need for external pneumatic drivers, and confirmed surgical feasibility through its first in vivo implantation. These advancements align with the SynCardia platform’s performance and position the device for chronic animal studies and clinical translation, signaling significant progress in the company’s artificial heart development. The results underscore potential long-term commercial viability and regulatory milestones, driving investor optimism.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet